The results of one study indicated that inhibition of ERK1/2 during priming, but not on the day of dyskinesia testing could attenuate LID50, suggesting that the primary role of ERK1/2 signaling may be in the development, rather than the expression of LID. The gene discussed is MAPK3; the disease is drug-induced dyskinesia.